James Whalen, MD
Psychiatry · Lincoln, RINPI 1134245954
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $81 of the $128 with a category attached, or 63.4%. 3 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 51.9% of the total. 2021 is the largest year on record at $59, 4.0 times the $15 reported in 2019.
Across 6 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$67
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
- Neurocrine Biosciences, Inc.$15
Across 123 payments — averaging $3515.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$242K
- Siemens Medical Solutions USA, Inc.$48K
- Janssen Research & Development, LLC$37K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$28K
- Supernus Pharmaceuticals, Inc.$19K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- plus $39K from 8 others
What the payments were for
- Food & beverage$8163%
- Education$4737%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
How this compares
$128 in reported general payments places this provider in the 60th percentile of 209 psychiatry providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 93 | $804,192 |
| Invega SustennaPaliperidone Palmitate | 145 | $445,634 |
| IngrezzaValbenazine Tosylate | 33 | $266,902 |
| Abilify MaintenaAripiprazole | 68 | $161,311 |
| VraylarCariprazine Hcl | 45 | $54,107 |
| CaplytaLumateperone Tosylate | 37 | $51,843 |
| Risperidone ErRisperidone Microspheres | 44 | $47,244 |
| Paliperidone ErPaliperidone | 212 | $38,659 |
| Clozapine | 397 | $26,257 |
| VivitrolNaltrexone Microspheres | 12 | $18,813 |
| Lurasidone Hcl | 28 | $8,320 |
| Buspirone Hcl | 530 | $8,309 |
| Aripiprazole | 170 | $7,784 |
| Atomoxetine Hcl | 80 | $7,446 |
| Mirtazapine | 267 | $6,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $15 | $266,90233 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $47 | $51,84337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 209 psychiatry providers in Rhode Island.
Other psychiatry in Lincoln
- Heather AbrahamsLincoln$6K
- Richard MillerCranston$864K
- Warren OngWarwick$807K
- James GreerProvidence$780K
- Mark ZimmermanCranston$225K
- Liliya KoyfmanWarwick$110K
- Linda CarpenterProvidence$37K
- Gene JacobsCranston$27K
- Terrie MailhotWarwick$26K
- Ethan KischWarwick$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.